🧬💣 Antibody–drug conjugates were designed as “magic bullets.” But a new 2026 JCI Review argues that the most successful ADCs are not really precision missiles—they are hybrid therapies combining targeted distribution with chemotherapy-like, spatially distributed killing. That distinction may explain why ADCs have transformed breast cancer treatment. ADC ≠ antibody + chemotherapy Instead: ANTIBODY determines where the drug preferentially travels LINKER determines where/when payload is released PAYLOAD determines what happens after release TUMOR MICROENVIRONMENT determines how far the effect spreads. Guo & Ellisen therefore propose a more nuanced view: ADCs are targeted primarily in BIODISTRIBUTION—not necessarily in CYTOTOXICITY. 207630.1-20260930212758-covered… That may be the key conceptual shift in this excellent review. 🎯 The original ADC model was simple Paul Ehrlich's “magic bullet” concept: ANTIBODY ↓ tumor antigen ↓ internalization ↓ lysosome ↓ payload release ↓ TARGET CELL DIES A conventional ADC contains: antibody linker cytotoxic payload. 207630.1-20260930212758-covered… But modern ADC biology is much messier—and more interesting. Today's effective ADCs can also act through: EXTRACELLULAR PAYLOAD RELEASE BYSTANDER KILLING Fc-MEDIATED IMMUNITY IMMUNOGENIC CELL DEATH TARGET-INDEPENDENT UPTAKE meaning an antigen-positive cell may function partly as a: LOCAL DRUG-DELIVERY HUB rather than the only cell destined to die. 207630.1-20260930212758-covered… 🔥 The clearest example: T-DM1 vs T-DXd Both target: HER2 and both use trastuzumab. Yet their clinical behavior is dramatically different. T-DM1 HER2 antibody noncleavable MCC linker DM1 tubulin inhibitor DAR ≈ 4 membrane-impermeable payload → essentially NO BYSTANDER EFFECT versus T-DXd HER2 antibody cathepsin-cleavable linker DXd TOP1 inhibitor DAR ≈ 8 membrane-permeable payload → STRONG BYSTANDER EFFECT. 207630.1-20260930212758-covered… 207630.1-20260930212758-covered… And the clinical difference is substantial. In DESTINY-Breast03: T-DXd PFS = 25.1 months versus T-DM1 = 7.2 months and in DESTINY-Breast05, 3-year invasive disease-free survival was: 92.4% vs 83.7%. 207630.1-20260930212758-covered… Same antibody. Same target. Very different drug. That tells us something fundamental: THE PAYLOAD–LINKER SYSTEM CAN MATTER AS MUCH AS THE ANTIBODY. 💥 BYSTANDER KILLING changed the meaning of “HER2-targeted” T-DM1 largely requires: HER2⁺ CELL → INTERNALIZATION → DEATH. But T-DXd can release membrane-permeable DXd that diffuses into neighboring: HER2-low or even HER2-negative cells. 207630.1-20260930212758-covered… This helps explain one of the biggest conceptual changes in breast oncology: HER2 is no longer merely an oncogenic driver. For an ADC, HER2 can also function as: A DELIVERY ADDRESS. That is why T-DXd works in: HER2-low and even HER2-ultralow breast cancer populations that would historically not have been considered candidates for HER2-targeted therapy. 207630.1-20260930212758-covered… 🧬 The same logic applies to TROP2 ADCs The FDA-approved breast cancer ADC landscape discussed in the review includes four major agents: T-DM1 → HER2 / DM1 T-DXd → HER2 / DXd Dato-DXd → TROP2 / DXd SG → TROP2 / SN-38. Three of these use: TOP1 INHIBITOR PAYLOADS and support bystander killing. 207630.1-20260930212758-covered… In metastatic TNBC, sacituzumab govitecan transformed treatment. In ASCENT: median PFS 5.6 vs 1.7 months median OS 12.1 vs 6.7 months versus chemotherapy. 207630.1-20260930212758-covered… The emergence of these drugs is particularly important because TNBC historically lacked strong target-selective therapeutic options. 🧪 LINKER chemistry may be the hidden pharmacology of ADCs Linkers determine: WHERE and WHEN the payload becomes pharmacologically active. Noncleavable linker: ADC → internalization → lysosomal degradation → payload Cleavable linker: ADC → protease / acidic pH / reducing environment → payload release and potentially: EXTRACELLULAR RELEASE. 207630.1-20260930212758-covered… This means ADC activity does not necessarily require every antibody molecule to enter a cancer cell. Extracellular proteases in the TME may cleave some linkers before internalization. For SG, acidic conditions can promote linker hydrolysis. Thus: TME BIOLOGY BECOMES PART OF ADC PHARMACOLOGY. ⚖️ More payload is NOT always better Another important concept is: DAR — drug-to-antibody ratio. Intuitively: higher DAR → more payload → better ADC. But biology disagrees. High DAR also causes: hydrophobicity ↑ aggregation ↑ clearance ↑ tolerability ↓. And the authors discuss the fascinating: “SATURATION FRONT” phenomenon. High-payload/high-affinity ADCs can bind rapidly to cells around tumor vessels. That creates: PERIVASCULAR SATURATION and prevents deeper tumor penetration. 207630.1-20260930212758-covered… So paradoxically: MORE DRUG PER ANTIBODY can sometimes mean LESS EFFECTIVE TUMOR DISTRIBUTION. 🤯 And perhaps <1% reaches the tumor One particularly sobering observation in the review: on-tumor ADC distribution is typically <1% of the administered dose. 207630.1-20260930212758-covered… That alone challenges the simplistic “precision missile” metaphor. Most ADC molecules do not end up neatly delivering their payload exclusively to antigen-positive cancer cells. This also helps explain why: OFF-TUMOR TOXICITY remains central to ADC pharmacology. ⚠️ Toxicity is often NOT caused by target expression Consider T-DXd. Its most concerning toxicity is: INTERSTITIAL LUNG DISEASE / PNEUMONITIS reported in up to ~15% of patients in the literature reviewed here. Yet the review emphasizes that this appears largely: TARGET-INDEPENDENT rather than simply HER2-mediated toxicity in lung epithelium. Preclinical work points toward ADC uptake by: ALVEOLAR MACROPHAGES. 207630.1-20260930212758-covered… Likewise, T-DM1-associated thrombocytopenia can involve: FcγRIIa-mediated uptake or macropinocytosis by megakaryocytes. 207630.1-20260930212758-covered… So ADC toxicity depends on: TARGET LINKER STABILITY PAYLOAD Fc BIOLOGY NONSPECIFIC CELLULAR UPTAKE. 🧠 Then comes the major biomarker problem We currently select ADCs largely using: TARGET EXPRESSION. But target abundance is an incomplete biomarker. ADC efficacy can depend on: antigen abundance antigen heterogeneity internalization receptor recycling lysosomal processing linker cleavage payload sensitivity efflux transporters apoptosis competence tumor penetration. The diagram in Figure 2, page 5 captures this beautifully. 207630.1-20260930212758-covered… So: HER2 IHC ≠ COMPLETE ADC BIOMARKER and TROP2 IHC ≠ COMPLETE ADC BIOMARKER. 🔄 Worse: the target itself changes during treatment HER2 is not static. Treatment pressure can shift tumors between: HER2-positive ↔ HER2-low ↔ HER2-zero. 207630.1-20260930212758-covered… After T-DXd progression: 49% of paired patient samples reportedly showed HER2 downregulation, and more than half of those showed: COMPLETE HER2 LOSS. 207630.1-20260930212758-covered… Resistance can also occur without antigen loss through HER2 binding-site mutations such as: V597M P593R which preserve surface expression but reduce trastuzumab binding. So a biopsy saying: “HER2 PRESENT” does not necessarily mean: “T-DXd CAN STILL BIND EFFECTIVELY.” 💣 PAYLOAD resistance may be equally important A tumor can preserve the ADC target but become resistant to its warhead. Examples include: lysosomal dysfunction SLC46A3 loss caveolin-mediated trafficking changes STAT3 activation PLK1 activation ABCC1 drug efflux. 207630.1-20260930212758-covered… And perhaps most strikingly: TOP1 MUTATIONS were detected in: 12.9% of patients progressing after TOP1i ADCs versus 0.7% in ADC-naive breast cancer. 207630.1-20260930212758-covered… Patients harboring these mutations had dramatically shorter responses to subsequent TOP1i ADCs: 52 vs 455 DAYS. 207630.1-20260930212758-covered… That provides a mechanistic explanation for: ADC CROSS-RESISTANCE. 🔁 This makes ADC SEQUENCING a major clinical problem Suppose a patient progresses on: T-DXd HER2 → DXd Should we switch to: SG TROP2 → SN-38? The antibody target changes. But both payloads inhibit: TOP1. Therefore: TARGET SWITCH ≠ MECHANISM SWITCH. Real-world analyses suggest cross-resistance is particularly problematic when sequential ADCs share payload mechanisms. 207630.1-20260930212758-covered… One multicenter study cited in the review found approximately: different payload class → ORR 22.6% same payload class → ORR 5.3% although PFS remained similar and these data remain retrospective. 207630.1-20260930212758-covered… This suggests future ADC sequencing may require something analogous to antimicrobial resistance testing: WHAT TARGET REMAINS? WHAT PAYLOAD IS THE TUMOR STILL SENSITIVE TO? 🧬 A future ADC biopsy may therefore need MULTI-DIMENSIONAL profiling Not simply: HER2 = 1+ but perhaps: HER2 abundance + spatial heterogeneity TROP2 abundance binding-site mutation status TOP1 status ABCC1 expression lysosomal function SLC46A3 DNA repair state TME penetration immune context. The review specifically highlights: quantitative immunofluorescence spatial antigen mapping and AI-assisted digital pathology as emerging approaches beyond conventional categorical IHC. 207630.1-20260930212758-covered… 🛡️ ADCs may also function as IMMUNOTHERAPY TOP1 inhibitor payloads can trigger: IMMUNOGENIC CELL DEATH including: calreticulin exposure HMGB1 release ATP release leading to: dendritic-cell activation → antigen presentation → T-cell priming. 207630.1-20260930212758-covered… The antibody component can additionally promote: ADCC via NK cells and ADCP via macrophages. Figure 3 on page 6 nicely illustrates how bystander killing, extracellular payload release, ADCC, ADCP, immunogenic cell death, stromal barriers and abnormal vasculature all interact within the TME. 207630.1-20260930212758-covered… So ADCs are potentially: TARGETED DELIVERY CHEMOTHERAPY IMMUNE MODULATION. 🔥 ADC + ICI combinations are already testing this idea In first-line PD-L1-positive advanced TNBC: SG + pembrolizumab improved PFS over chemotherapy + pembrolizumab in ASCENT-04. And in BEGONIA: Dato-DXd + durvalumab produced approximately: 80% ORR regardless of PD-L1 expression. 207630.1-20260930212758-covered… But the story is not universally positive. T-DXd + nivolumab has so far produced response rates broadly comparable with historical T-DXd monotherapy. And DAISY biomarker analyses did not show a clear increase in granzyme-B⁺ CD8 T cells during T-DXd therapy. 207630.1-20260930212758-covered… So: ICD IN MICE ≠ GUARANTEED ICI SYNERGY IN HUMANS. That translational distinction is important. 🧬 Another rational combination: ADC + PARP inhibition TOP1 inhibitors trap: TOP1 cleavage complexes on DNA. PARP inhibition can further prevent repair of this damage. Thus: TOP1i ADC PARPi = DNA DAMAGE AMPLIFICATION. 207630.1-20260930212758-covered… The interesting pharmacological idea is that ADC delivery may create a larger: TUMOR : NORMAL PAYLOAD GRADIENT allowing sequential ADC/PARPi dosing that might be too toxic if both drugs were delivered systemically. 🚀 But the FUTURE of ADCs may look nothing like chemotherapy This is perhaps the most exciting part of the review. The next generation expands along: THREE AXES 1️⃣ NEW TARGETS Beyond HER2 and TROP2: HER3 Nectin-4 mesothelin FOLR1 B7-H3 B7-H4 Claudin 18.2 LIV1 ROR1/ROR2 tissue factor. And even: CANCER-ASSOCIATED FIBROBLASTS or ENDOTHELIAL CELLS can become ADC targets. 207630.1-20260930212758-covered… That represents another conceptual shift: THE ANTIBODY DOESN'T EVEN HAVE TO TARGET THE CANCER CELL. A stromal target can function as an anchor for local payload release. 2️⃣ NEW PAYLOADS Future ADC-like conjugates may carry: 🧬 siRNA ♻️ PROTACs 🧲 molecular glues 🛡️ STING agonists 🔥 TLR7/8 agonists ☢️ radionuclides 💡 photosensitizers ☠️ immunotoxins ✍️ α-amanitin. 207630.1-20260930212758-covered… Table 4 on page 10 shows just how far the field has moved beyond conventional cytotoxic payloads. 207630.1-20260930212758-covered… Perhaps eventually the term: ANTIBODY–DRUG CONJUGATE will become too narrow. These are increasingly: ANTIBODY-GUIDED MOLECULAR DELIVERY PLATFORMS. 3️⃣ SMARTER ANTIBODIES Next-generation engineering includes: biparatopic ADCs → two epitopes on one antigen bispecific ADCs → two different antigens dual-payload ADCs → two different warheads probody ADCs → masked until activated in the TME Fc engineering → tune immunity / half-life